Technology
5N Plus Inc. Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Published
2 years agoon
By
19% growth in annual revenue to $289.3 million39% growth in annual Adjusted EBITDA1 to a record $53.3 millionAnnual Adjusted gross margin percentage1 of 31.6%Backlog1 of $252.8 million, representing 326 days of annualized revenue, as at December 31, 2024Increases 2025 Adjusted EBITDA guidance to a range of $55 to $60 million
MONTREAL, Feb. 25, 2025 /CNW/ – 5N Plus Inc. (TSX: VNP) (“5N+” or “the Company”), a leading global producer of specialty semiconductors and performance materials, today announced its financial results for the fourth quarter of fiscal 2024 (“Q4 2024”) and fiscal year (“FY 2024”) ended December 31, 2024. All amounts in this press release are expressed in U.S. dollars unless otherwise stated.
“We had an outstanding year in FY 2024, generating stellar financial and operational results. We generated record annual Adjusted EBITDA representing 39% growth over the previous year, delivered on our margin expansion efforts, and sustained an elevated backlog and a solid balance sheet. We also successfully increased capacity at several sites to meet demand in strategic sectors, with work underway to increase solar cell capacity at AZUR by an additional 30% this year, on top of the 35% achieved last year. Looking at our segments, in Specialty Semiconductors, we continued to benefit from our unique position as the leading supplier outside China and trusted partner in the growing terrestrial renewable energy and space solar power sectors. In Performance Materials, our improved product mix and solid operational execution also contributed to strong profitability,” said Gervais Jacques, President and CEO of 5N+.
“Our strategic focus on higher margin, value-added advanced materials and on being a critical supplier without being a critical cost to customers operating in growing markets continues to pay off. This is further supported by our recognition as a reliable partner and market leader with unique expertise and manufacturing capabilities. With our resilient and agile business model as our foundation, we will continue to leverage our strategic positioning and competitive advantages to build on our FY 2024 momentum as we enter 2025 and forge ahead on our profitable growth path,” concluded Mr. Jacques.
Financial Highlights
Revenue in Q4 2024 increased by 9% to $70.9 million, compared to $65.1 million in Q4 2023, driven by strong growth under Specialty Semiconductors. Revenue in FY 2024 reached $289.3 million, compared to $242.4 million in FY 2023, supported by the terrestrial renewable energy and space solar power sectors under Specialty Semiconductors.Adjusted EBITDA in Q4 2024 increased by 38% to $12.5 million, compared to $9.0 million in Q4 2023, driven by higher volume from the terrestrial renewable energy and space solar power sectors, and better prices over inflation. Adjusted EBITDA was $53.3 million in FY 2024, representing a 39% increase compared to $38.3 million in FY 2023.Adjusted gross margin1 increased by 26% to $23.4 million in Q4 2024, favourably impacted by the same factors as above. Adjusted gross margin as a percentage of sales was 33.0% in Q4 2024, compared to 28.5% in Q4 2023. Adjusted gross margin reached $91.3 million for FY 2024, or 31.6% of sales, compared to $70.2 million in FY 2023, or 29.0% of sales.Net earnings in Q4 2024 were $1.0 million, compared to $2.3 million in Q4 2023. For FY 2024, net earnings were $14.7 million, compared to $15.4 million in FY 2023.Backlog stood at $252.8 million, representing 326 days of annualized revenue as at December 31, 2024, 37 days higher than the previous quarter and 34 days higher than at the end of last year, primarily due to the timing of contract signings and renewals.Net debt1 was $100.1 million as at December 31, 2024, compared to $73.8 million as at December 31, 2023, reflecting an increase in working capital1 and planned capital expenditures in 2024 under Specialty Semiconductors. The Company’s net debt to EBITDA ratio1 stood at 2.02x as at December 31, 2024.
____________________________
1 These measures are not recognized measures under IFRS and do not have standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures presented by other companies. See Non-IFRS Measures for more information.
Market Outlook
In Specialty Semiconductors, 5N+ continues to benefit from its unique position as the leading global supplier of ultra-high purity semiconductor compounds outside China, with long-term partnerships with key customers. Growing demand remains the rule, particularly in terrestrial renewable energy and space solar power. 5N+ is well-positioned to capitalize on future opportunities in these high-growth sectors.
The Company also anticipates growth under imaging and sensing applications including in the security, defence and medical sectors. The anticipated transition to photon counting detector (PCD) technology for medical imaging is anticipated to provide a promising growth avenue in the medium term.
Management expects growth in the Performance Materials segment to be primarily driven by the health and pharmaceutical sector, which provides high profitability and predictable cashflows. We expect demand for bismuth chemicals to continue to grow in line with GDP in respective markets.
As a result of increased production capacity and operational flexibility, 5N+ is in a position to efficiently capture additional organic growth opportunities in the near term, while it also actively pursues external growth opportunities.
Based on under-contract and anticipated near-term demand primarily driven by the Specialty Semiconductors segment, management anticipates generating Adjusted EBITDA in a range of $55 to $60 million in 2025, representing an upward revision of its previously disclosed range of $50 to $55 million.
The recent change in administration in the U.S. creates uncertainty in the global economic outlook, particularly regarding potential trade protectionist measures that could trigger retaliatory actions from affected countries. Given the rapidly evolving landscape and the potential impact of these measures, the Company has elected to defer providing guidance for 2026 until it has had the opportunity to further assess the direct and indirect impacts on its business and operations. The Company remains committed to its long-term objectives and the execution of its strategic initiatives.
The Company intends to leverage its strategic positioning and competitive advantages to build on its FY 2024 momentum as it enters 2025 and to navigate any potential headwinds that result from the evolving macro-economic and geopolitical environment.
Conference Call
5N+ will host a conference call on Wednesday, February 26, 2025, at 8:00 a.m. Eastern Time to discuss Q4 and FY 2024 financial results. All interested parties are invited to participate in the live broadcast on the Company’s website at www.5nplus.com.
To participate in the conference call:
Toronto area: 289-819-1299Toll‐Free: 1-800-990-4777Enter access code: 71321
A replay of the conference call will be available two hours after the event and until March 5, 2025. To access the recording, please dial 1-888-660-6345 and enter access code 71321.
________________________________
1 These measures are not recognized measures under IFRS and do not have standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures presented by other companies. See Non-IFRS Measures for more information.
About 5N+
5N+ is a leading global producer of specialty semiconductors and performance materials. The Company’s ultra‐pure materials often form the core element of its customers’ products. These customers rely on 5N+’s products to enable performance and sustainability in their own products. 5N+ deploys a range of proprietary and proven technologies to develop and manufacture its products. The Company’s products enable various applications in several key industries, including renewable energy, security, space, pharmaceutical, medical imaging and industrial. Headquartered in Montréal, Quebec, 5N+ operates R&D, manufacturing and commercial centers in strategically located facilities around the world including Europe, North America and Asia.
Forward‐Looking Statements
Certain statements in this press release may be forward‐looking within the meaning of applicable securities laws. Such forward‐looking statements are based on a number of estimates and assumptions that the Company believes are reasonable when made, including that 5N+ will be able to retain and hire key personnel and maintain relationships with customers, suppliers and other business partners, that 5N+ will continue to operate its business in the normal course, that 5N+ will be able to implement its growth strategy, that 5N+ will be able to successfully and timely complete the realization of its backlog, that 5N+ will not suffer any supply chain challenges or any material disruption in the supply of raw materials on competitive terms, that 5N+ will be able to generate new sales, produce, deliver, and sell its expected product volumes at the expected prices and control its costs, as well as other factors believed to be appropriate and reasonable in the circumstances. However, there can be no assurance that such estimates and assumptions will prove to be correct. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict and may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward‐looking statements. A description of the risks affecting the Company’s business and activities appears under the heading “Risk and Uncertainties” of the Company’s 2024 MD&A dated February 25, 2025, available on www.sedarplus.ca.
Forward‐looking statements can generally be identified by the use of terms such as “may”, “should”, “would”, “believe”, “expect”, the negative of these terms, variations of them or any similar terms. No assurance can be given that any events anticipated by the forward‐looking statements in this press release will transpire or occur, or if any of them do so, what benefits that 5N+ will derive therefrom. In particular, no assurance can be given as to the future financial performance of 5N+. The forward‐looking statements contained in this press release is made as of the date hereof and the Company has no obligation to publicly update such forward‐looking information to reflect new information, subsequent or otherwise, unless required by applicable securities laws. The reader is warned against placing undue reliance on these forward‐looking statements. Forward-looking statements are presented in this press release for the purpose of assisting investors and others in understanding certain key elements of the Company’s expected financial results, as well as the Company’s objectives, strategic priorities and outlook, and in obtaining a better understanding of the Company’s anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes.
5N PLUS INC.
CONSOLIDATED STATEMENTS OF EARNINGS
Years ended December 31
(in thousands of United States dollars, except per share information)
2024
2023
$
$
Revenue
289,281
242,371
Cost of sales
211,413
184,833
Selling, general and administrative expenses
34,026
29,410
Other expenses (income), net
11,614
756
257,053
214,999
Operating earnings
32,228
27,372
Financial expenses
Interest on long-term debt
8,210
8,262
Imputed interest and other interest expense
959
572
Foreign exchange gain
(549)
(136)
8,620
8,698
Earnings before income taxes
23,608
18,674
Income tax expense (recovery)
Current
6,945
6,674
Deferred
1,991
(3,399)
8,936
3,275
Net earnings
14,672
15,399
Basic earnings per share
0.17
0.17
Diluted earnings per share
0.16
0.17
Net earnings are completely attributable to equity holders of 5N+.
5N PLUS INC.
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(in thousands of United States dollars)
December 31
2024
December 31
2023
$
$
Assets
Current
Cash
22,142
34,706
Accounts receivable
42,172
33,437
Inventories
137,823
105,850
Income tax receivable
1,811
1,672
Derivative financial assets
6,978
591
Other current assets
6,469
5,707
Total current assets
217,395
181,963
Property, plant and equipment
85,995
84,600
Right-of-use assets
28,583
29,290
Intangible assets
22,929
29,304
Goodwill
10,665
11,825
Deferred tax assets
7,358
8,261
Other assets
3,982
4,959
Total non-current assets
159,512
168,239
Total assets
376,907
350,202
Liabilities
Current
Trade and accrued liabilities
42,116
37,024
Income tax payable
5,207
4,535
Current portion of deferred revenue
11,206
13,437
Current portion of lease liabilities
1,952
1,811
Current portion of long-term debt
–
25,000
Total current liabilities
60,481
81,807
Long-term debt
122,203
83,500
Deferred tax liabilities
5,737
5,284
Employee benefit plan obligations
12,624
13,393
Lease liabilities
27,450
28,328
Deferred revenue
8,688
5,629
Other liabilities
706
3,669
Total non-current liabilities
177,408
139,803
Total liabilities
237,889
221,610
Equity
139,018
128,592
Total liabilities and equity
376,907
350,202
Non‐IFRS Measures
EBITDA means net earnings (loss) before interest expenses, income tax expense (recovery), depreciation and amortization. 5N+ uses EBITDA because it believes it is a meaningful measure of the operating performance of its ongoing business, without the effects of certain expenses. The definition of this non-IFRS measure used by the Company may differ from that used by other companies.
EBITDA is reconciled to the most comparable IFRS measure:
(in thousands of U.S. dollars)
Q4 2024
Q4 2023
FY 2024
FY 2023
$
$
$
$
Net earnings
1,006
2,284
14,672
15,399
Interest on long-term debt, imputed interest and other interest expense
2,446
2,129
9,169
8,834
Income tax expense (recovery)
2,415
(734)
8,936
3,275
Depreciation and amortization
4,373
4,057
16,791
16,110
EBITDA
10,240
7,736
49,568
43,618
EBITDA margin is defined as EBITDA divided by revenues.
Adjusted EBITDA means operating earnings (loss) as defined before the effect of impairment of inventories, share-based compensation expense (recovery), loss (gain) on disposal of property, plant and equipment, loss (gain) on remeasurement of financial instrument, impairment (reversal of impairment) of non-current assets, litigation and restructuring costs (income), and depreciation and amortization. 5N+ uses Adjusted EBITDA because it believes it is a meaningful measure of the operating performance of its ongoing business without the effects of certain expenses. The definition of this non-IFRS measure used by the Company may differ from that used by other companies.
Adjusted EBITDA margin is defined as Adjusted EBITDA divided by revenues.
Adjusted EBITDA and Adjusted EBITDA margin are reconciled to the most comparable IFRS measure:
(in thousands of U.S. dollars)
Q4 2024
Q4 2023
FY 2024
FY 2023
$
$
$
$
Revenues
70,854
65,063
289,281
242,371
Operating expenses
(64,701)
(61,023)
(257,053)
(214,999)
Operating earnings
6,153
4,040
32,228
27,372
Share-based compensation expense
309
414
906
1,432
(Gain) loss on disposal of property, plant and equipment
–
–
(2,089)
1,051
Loss on remeasurement of financial instrument
1,000
–
1,000
–
(Reversal of impairment) impairment of non-current assets
(120)
64
2,706
672
Litigation and restructuring costs (income)
769
458
1,790
(8,314)
Depreciation and amortization
4,373
4,057
16,791
16,110
Adjusted EBITDA
12,484
9,033
53,332
38,323
Adjusted EBITDA margin
17.6 %
13.9 %
18.4 %
15.8 %
Adjusted gross margin is a measure used to monitor the sales contribution after paying cost of sales, excluding depreciation and inventory impairment charges. 5N+ also expressed this measure in percentage of revenues by dividing the adjusted gross margin value by the total revenue.
Adjusted gross margin is reconciled to the most comparable IFRS measure:
(in thousands of U.S. dollars)
Q4 2024
Q4 2023
FY 2024
FY 2023
$
$
$
$
Total revenue
70,854
65,063
289,281
242,371
Cost of sales
(51,104)
(49,677)
(211,413)
(184,833)
Gross margin
19,750
15,386
77,868
57,538
Depreciation included in cost of sales
3,643
3,189
13,445
12,656
Adjusted gross margin
23,393
18,575
91,313
70,194
Adjusted gross margin percentage
33.0 %
28.5 %
31.6 %
29.0 %
Backlog represents the expected orders the Company has received, but has not yet executed, and that are expected to translate into sales within the next twelve months, expressed in dollars and estimated in number of days not to exceed 365 days. Bookings represent orders received during the period considered, expressed in number of days, and calculated by adding revenues to the increase or decrease in backlog for the period considered, divided by annualized year revenues. 5N+ uses backlog to provide an indication of expected future revenues in days, and bookings to determine its ability to sustain and increase its revenues.
Net debt is calculated as total debt less cash. Any introduced IFRS 16 reporting measures in reference to lease liabilities are excluded from the calculation. 5N+ uses this measure as an indicator of its overall financial position.
The net debt to EBITDA ratio is defined as net debt divided by the trailing 12 months EBITDA.
Total debt and Net debt are reconciled to the most comparable IFRS measure:
(in thousands of U.S. dollars)
As at December 31, 2024
As at December 31, 2023
$
$
Bank indebtedness
–
–
Long-term debt including current portion
122,203
108,500
Lease liabilities including current portion
29,402
30,139
Subtotal Debt
151,605
138,639
Lease liabilities including current portion
(29,402)
(30,139)
Total Debt
122,203
108,500
Cash
(22,142)
(34,706)
Net Debt
100,061
73,794
Working capital is a measure of liquid assets that is calculated by taking current assets and subtracting current liabilities. Given that the Company is currently indebted, it uses it as an indicator of its financial efficiency and aims to maintain it at the lowest possible level.
Working capital ratio is calculated by dividing current assets by current liabilities.
Working capital is reconciled to the most comparable IFRS measure:
(in thousands of U.S. dollars)
As at December 31, 2024
As at December 31, 2023
$
$
Inventories
137,823
105,850
Other current assets excluding inventories
79,572
76,113
Current assets
217,395
181,963
Current liabilities
(60,481)
(81,807)
Working capital
156,914
100,156
Working capital ratio
3.59
2.22
SOURCE 5N Plus Inc.
You may like
Technology
Primitive Labs Announces Sony Innovation Fund Investment to Advance AI Models of Human Behavior
Published
41 minutes agoon
October 5, 2026By
Company’s Instinct platform uses behavioral simulation to help enterprises anticipate customers engagement within digital products and experiences before launch
SAN FRANCISCO and TOKYO, Oct. 5, 2026 /PRNewswire/ — Primitive Labs, an AI research and product company developing models of human behavior, announced today an investment from Sony Innovation Fund. The funding continues the company’s behavioral modeling research and the development of Instinct, an enterprise platform for companies to model their customers and simulate their interactions before launch.
AI has accelerated the capacity to build and operate software autonomously; however, one layer is overlooked. Primitive Labs is building an architecture for human behavior to solve this missing layer. Its research centers on building models that represent how people form goals, change beliefs, and make decisions. Under pressures like uncertainty or time, people will either persist or abandon their objectives. Primitive Labs is creating the foundation for AI systems to be able to reason human behavior, rather than simply predicting the next action.
Instinct brings this research into the product development cycle. With an organization’s user research, product analytics, and behavioral data, the platform creates simulated customer populations to navigate digital experiences. Teams across product, design, research can use the simulations to examine likely customer outcomes. Instinct helps customers de-risk critical user funnels by identifying points of abandonment, while comparing how different audiences respond, before committing to a launch or major product decision.
“The barrier to building software is dropping, but the expectations of users hasn’t changed,” said Rohit Talluri, CEO and Co-Founder of Primitive Labs. “We think understanding people should be a capability of the technology itself, something we can train and test, rather than a separate exercise trying to keep up with every release. Companies should be able to build with a model of the people they serve from the beginning.”
“As enterprises become more agentic, one of the core areas that our team has been evaluating is the customer journey,” said Atsushi Kitagawa, Managing Director-US, Sony Ventures. “Primitive Labs is taking a compelling research-driven approach to modeling human behavior, with the potential to help enterprises better anticipate how customers will respond to digital experiences. We’re excited by the opportunity ahead and believe Rohit and the team have the technical expertise and commercial experience to execute on this vision.”
Modeling How People Make Decisions
Primitive Labs is working with partners across retail, e-commerce, media and entertainment, advertising, and gaming. These engagements focus on high-value journeys such as onboarding, account creation, subscription, and checkout, including how those experiences may need to change for different customer segments or new markets.
Across their research, the company has generated hundreds of thousands of simulated behavioral trajectories across hundreds of customer populations and thousands of digital environments, creating a growing dataset used to train and improve the fidelity of its behavioral models.
Primitive Labs sees longer-term opportunities in healthcare and life sciences, financial services, travel, marketplaces, and other sectors where understanding how people make decisions is central to the customer experience.
Primitive Labs was founded in 2026 by Rohit Talluri (CEO), Jean Farmer (CTO), and Gabriel Fong (COO), who first worked together at Amazon Web Services (AWS). Talluri later worked in Amazon’s Artificial General Intelligence Autonomy Lab, supporting computer-use agent initiatives. Farmer worked in Amazon AGI and supported the Amazon Nova launches. The broader team brings professional and academic experience from Amazon, Google, Harvard, MIT, and the University of Washington.
Primitive Labs is also backed by a16z speedrun, Andreessen Horowitz’s early-stage startup program, and is a member of its SR007 cohort.
“There’s a real difference between asking AI to act like a person and building models of how people actually behave,” said Josh Lu, Investment Partner at Andreessen Horowitz for a16z speedrun. “We backed Rohit, Jean, and Gabe because they uniquely have both the AI research and commercial expertise to build a new class of behavioral models for enterprises. As building software becomes easier, we believe understanding the people you’re building for will be as essential as the code itself. Instinct is the beginning of the shift by bringing a model of the customer into the development process. It will shape how products get built and more importantly, what teams decide is worth building in the first place.”
About Primitive Labs
Primitive Labs is an AI research and product company developing models of human behavior. The company brings together the human behavior architecture with training systems to apply those models in software. Its first product, Instinct, enables enterprises to model customer populations and simulate how they interact with digital experiences before launch. Primitive Labs’ mission is to make human behavior a first-class primitive in software development. Founded in 2026 and headquartered in San Francisco, Primitive Labs is backed by a16z speedrun, Sony Innovation Fund, Olive Tree Capital, Pack Ventures, and technology leaders with backgrounds spanning OpenAI, Google DeepMind, Amazon, and Uber.
Learn more at primitivelabs.ai.
View original content to download multimedia:https://www.prnewswire.com/news-releases/primitive-labs-announces-sony-innovation-fund-investment-to-advance-ai-models-of-human-behavior-302898086.html
SOURCE Primitive Labs AI Inc.
Technology
Robin Roberts Headlines the Melanoma Research Foundation’s 25th Annual New York Gala
Published
41 minutes agoon
October 5, 2026By
The Melanoma Research Foundation (MRF) will host its 25th Annual New York Gala on Thursday, October 15, at Guastavino’s, marking a milestone celebration of the Gala’s 25-year history and the MRF’s 30 years of advancing melanoma research, education and advocacy. The inspirational evening will bring together members of the melanoma community, philanthropists, researchers, advocates and supporters to honor those making an impact and raise critical funds to accelerate treatment innovation and progress toward a cure for a disease that affects more than 1.4 million Americans.
NEW YORK, Oct. 5, 2026 /PRNewswire-PRWeb/ — “Good Morning America” Co-Anchor and President of Rock’n Robin Productions to Emcee Milestone Event Celebrating 25 Years of the NYC Gala and 30 Years of the MRF
New York City, NY (October 5, 2026) – The Melanoma Research Foundation (MRF) will host its 25th Annual New York Gala on Thursday, October 15, at Guastavino’s, marking a milestone celebration of the Gala’s 25-year history and the MRF’s 30 years of advancing melanoma research, education and advocacy. The inspirational evening will bring together members of the melanoma community, philanthropists, researchers, advocates and supporters to honor those making an impact and raise critical funds to accelerate treatment innovation and progress toward a cure for a disease that affects more than 1.4 million Americans.
The milestone Gala is honored to welcome Robin Roberts, Co-Anchor of “Good Morning America” and President of Rock’n Robin Productions, as this year’s emcee.
With a goal of raising $1.3 million, Gala attendees, donors and sponsors will foster a legacy of hope and progress for the melanoma community. Funds raised through the event will support the MRF’s mission, including elevating prevention and awareness of melanoma, supporting all melanoma patients through educational programs, funding innovative research grants that lead to more therapeutics and novel clinical trials and advancing federal and state-level advocacy initiatives.
“For three decades, the MRF has been a committed and impactful thought leader in melanoma patient advocacy,” said Kyleigh LiPira, CEO of the Melanoma Research Foundation. “As we celebrate the 25th anniversary of our New York Gala, we are reminded of what is possible when our community comes together with a shared commitment to enabling life-saving research, education, advocacy and hope. This milestone evening is an opportunity to celebrate how far we’ve come while investing in the discoveries and breakthroughs that will ultimately benefit melanoma patients and their loved ones.”
Throughout the event, the MRF will present and honor Miguel A. Materin, MD with the CURE OM Vision of Hope Award for his commitment to fighting melanoma through exemplary patient care, cutting edge research and scientific leadership and Elta MD will be presented with the Corporate Leadership Award for their longstanding commitment to sun safety and skin health. Three courage awards will be presented to individuals whose courageous stories inspire the melanoma community including Jason Chambers, Sara Corrado and Lindsay Held. Whitney Bowe, MD, FAAD will receive the Excellence in Prevention Award for her unparalleled dedication to the prevention of melanoma, and the compassion with which she treats their patients.
Gala attendees will celebrate the melanoma community through a seated dinner, once-in-a-lifetime auction items and experiences, special presentations and an exciting Fund-a-Grant that will help enable the next groundbreaking treatment.
The MRF thanks its event co-chairs including Terry and Doug Brodman, Elyse Love, MD, FAAD and Anthony and Carly Manginelli, its auction and volunteer co-chairs and host committee. Their leadership and commitment have played an integral role in bringing the 25th Annual New York Gala to life.
To purchase a ticket, sponsorship or to make a donation, click here.
About the Melanoma Research Foundation (MRF)
The Melanoma Research Foundation (MRF) is the largest independent organization devoted to melanoma. Committed to the support of medical research in finding effective treatments and eventually a cure for melanoma, the MRF also educates patients and physicians about prevention, diagnosis, and the treatment of melanoma and the melanoma rare subtypes. The MRF is a committed advocate for the melanoma community, helping to raise awareness of this disease and the need for a cure. The MRF’s website (www.melanoma.org) is the premier source for melanoma information seekers. Find the MRF on Facebook, Twitter, Instagram and TikTok.
Media Contact
James Merrick
Chief Communications and Marketing Officer
jmerrick@melanoma.org
Media Contact
James Merrick, Melanoma Research Foundation, 1 2025793450, jmerrick@melanoma.org, melanoma.org
View original content to download multimedia:https://www.prweb.com/releases/robin-roberts-headlines-the-melanoma-research-foundations-25th-annual-new-york-gala-302898164.html
SOURCE Melanoma Research Foundation
Technology
Waterloo Regional Health Network Extends 3terra Data Quality Platform Network-Wide
Published
41 minutes agoon
October 5, 2026By
Three-year agreement applies a single set of coded data quality checks across WRHN sites as the merged organization integrates
KITCHENER, ON, Oct. 5, 2026 /CNW/ – Waterloo Regional Health Network (WRHN) has signed a three-year agreement to extend the 3terra Data Quality Assist (DQA) platform across its full network, giving Health Information Management and Decision Support teams a consistent view of coded data quality at every site.
WRHN was formed on April 1, 2025 through the merger of Grand River Hospital and St. Mary’s General Hospital. The WRHN @ Midtown site has used DQA since 2019. The new agreement extends the platform to the rest of the network, standardizing how coding accuracy and data quality are monitored across the combined organization.
Hospital mergers change coding workflows, information systems and teams, conditions that put coded data quality at risk at any organization. Because coded data drives patient-based funding and the performance reporting leadership relies on, WRHN is applying a single set of quality checks across all sites from the outset, giving its teams visibility into issues as they emerge rather than after they have reached funding or reporting.
Consistent coded data across sites also supports network-level analysis. WRHN’s Decision Support team can compare activity, monitor performance, and build reporting on the same verified foundation, without reconciling different data quality practices inherited from two organizations. DQA is used by more than 70% of Ontario hospitals funded under Health System Funding Reform (HSFR), so the checks now applied across WRHN reflect a standard already in place across the province.
“Bringing our sites onto one data quality standard is part of building one organization. Our teams shouldn’t have to reconcile two inherited approaches to know the data is right — this gives everyone at WRHN the same verified foundation from day one.” – Anh Tran, Director, Decision Support & Business Intelligence, Waterloo Regional Health Network
“A merger touches nearly every process that produces coded data. WRHN’s decision to apply one standard across the whole network means their teams can identify issues as they happen and act on them, at the point where reliable data matters most.” – Iain Robinson, CEO, 3terra
About Waterloo Regional Health Network: Waterloo Regional Health Network (WRHN, pronounced wren) represents the merger of two Hospitals into a single, integrated healthcare organization. Built on over 90 years of partnership, WRHN is home to seven regional programs and comprehensive healthcare services to meet the current and emerging needs in Waterloo-Wellington and beyond. WRHN is redefining the healthcare experience through collaboration and innovation, addressing barriers to access, advancing care delivery, and setting new standards in compassionate, empowered, community-driven healthcare. At WRHN, we provide outstanding care that’s personal, seamless, and reimagined.
About 3terra: For more than two decades, 3terra has been a trusted analytics partner to Canadian hospitals, with deep expertise in the data quality and analytical demands unique to the Canadian health system. The DQA platform is purpose-built for the realities of hospital operations, helping health information management and decision support teams ensure data accuracy, drive improvement initiatives, and equip leadership with the insights needed to act. For more information, visit www.3terra.com or contact info@3terra.com.
SOURCE 3terra
Primitive Labs Announces Sony Innovation Fund Investment to Advance AI Models of Human Behavior
Robin Roberts Headlines the Melanoma Research Foundation’s 25th Annual New York Gala
Waterloo Regional Health Network Extends 3terra Data Quality Platform Network-Wide
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
Nullmax and Renesas Forge Strategic Partnership to Deliver Competitive ADAS Solutions for the Global Market
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Coin Market4 days agoCrypto hacks top $768M in September, worst month of 2026
-
Coin Market4 days agoChainalysis beats most Celsius claims, but ‘audit’ lawsuit survives
-
Technology5 days agoMore Brands Break the US$1 Million Mark as Lazada Celebrates Partner Growth
-
Coin Market5 days agoBase completes Cobalt upgrade, adds new tools for tokenized assets
-
Near Videos5 days agoBuilding Private AI
-
Coin Market5 days agoStandard Chartered sees Ethena’s USDe reaching $40B, ENA hitting $2
-
Technology4 days agoAngel Aligner Upgrades Torque Ridges to “Pressure Points” in Europe
-
Technology3 days agoNasdaq Fund Secondaries, LODAS Markets Complete First Interval Fund Auction with Harrison Street Private Wealth
